BofA raised the firm’s price target on Arcus Biosciences (RCUS) to $26 from $17 and keeps a Neutral rating on the shares after incorporating Taiho’s option of RCC candidate casdatifan in its Arcus model while making “limited adjustments” to its forecasts following the company’s Q3 earnings update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Completes Successful Stock Offering
- Arcus Biosciences 13.7M share Spot Secondary priced at $18.25
- Arcus Biosciences TBA Spot Secondary; price range $18.25-$18.75
- Arcus Biosciences announces common stock offering, no amount given
- Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs